000 01265cam a2200169 4500500
005 20250121083954.0
041 _afre
042 _adc
100 1 0 _aHajjaji, Nawale
_eauthor
700 1 0 _a Tredan, Olivier
_eauthor
245 0 0 _aTriple-negative breast cancer: From biology to clinical practice
260 _c2022.
500 _a68
520 _aTriple-negative breast cancers (TNBC) are a large heterogeneous group of pathological and biologically diverse carcinomas. TNBC may be categorized based on distinct genomic or transcriptional patterns and/or immune characteristics, and classified as basal-like, mesenchymal, and luminal androgen-receptor subtypes. They may be highly infiltrated by immune cells or devoid of them. Molecular alterations should be screened to help define the treatment. Thus, there is a need to adopt a comprehensive view of TNBC biology in order to tailor the therapeutic strategy with targeted agents, including novel antibody-drug conjugates or innovative immunotherapies.
786 0 _nInnovations & Thérapeutiques en Oncologie | Volume 8 | Special Issue 2 | 2022-12-02 | p. 5-11 | 2431-3203
856 4 1 _uhttps://shs.cairn.info/journal-innovations-therapeutiques-en-oncologie-2025-HS2-page-5?lang=en&redirect-ssocas=7080
999 _c504562
_d504562